A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Diagnosed with gastroparesis
• Demonstrated delayed gastric emptying
• Presence of moderate to severe nausea
• Body Mass Index (BMI) of ≥18 and ≤40 kg/m2
Locations
Other Locations
Belgium
Vanda Investigational Site
RECRUITING
Leuven
Vanda Investigational Site
RECRUITING
Liège
Germany
Vanda Investigational Site
RECRUITING
Leipzig
Contact Information
Primary
Vanda Pharmaceuticals
clinicaltrials@vandapharma.com
202-734-3400
Time Frame
Start Date: 2024-01-09
Estimated Completion Date: 2025-12
Participants
Target number of participants: 100
Treatments
Experimental: Open Label Tradipitant
Oral Capsule
Related Therapeutic Areas
Sponsors
Leads: Vanda Pharmaceuticals